Skip to main content
Premium Trial:

Request an Annual Quote

EraGen Gets Nod to Market Five RT-PCR Tests in Canada

NEW YORK (GenomeWeb News) - EraGen Biosciences said today that it has received Health Canada approval to market five quantitative PCR-based in vitro diagnostics in the Canadian market.
 
Health Canada approved the company’s tests for Bordetella pertussis and B. parapertussis; Enterovirus; influenza types A and B; herpes simplex virus 1 and 2; and cytomegalovirus.
 
Madison, Wisc.-based EraGen performs the tests on its MultiCode-RTx real-time PCR system, which the company said “simplifies and enhances” real-time PCR through the use of a synthetic base pair, called isoC and isoG.
 
Irene Hrusovsky, president and chief executive of EraGen, said in a statement that the approvals “reinforce EraGen's commitment to international expansion.”

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.